Gene · 64798
Papers1,775
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 1,775
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets. | Int J Mol Sci | 2022 | 36077374 | PubTator, text mining | PubMed |
| Endocrine therapy resistance: what we know and future directions. | Explor Target Antitumor Ther | 2022 | 36071983 | PubTator, text mining | PubMed |
| Using human induced pluripotent stem cell-derived cardiomyocytes to understand the mechanisms driving cardiomyocyte maturation. | Front Cardiovasc Med | 2022 | 36061558 | PubTator, text mining | PubMed |
| An integrative pan-cancer analysis revealing the difference in small ring finger family of SCF E3 ubiquitin ligases. | Front Immunol | 2022 | 36059474 | PubTator, text mining | PubMed |
| Associations between depressive symptoms and quality of life among residents of Wuhan, China during the later stage of the COVID-19 pandemic: A network analysis. | J Affect Disord | 2022 | 36058363 | PubTator, text mining | PubMed |
| tRNA-Derived Fragment tRF-5009A Regulates Autophagy and Degeneration of Cartilage in Osteoarthritis via Targeting mTOR. | Oxid Med Cell Longev | 2022 | 36035226 | PubTator, text mining | PubMed |
| Norcantharidin overcomes vemurafenib resistance in melanoma by inhibiting pentose phosphate pathway and lipogenesis via downregulating the mTOR pathway. | Front Pharmacol | 2022 | 36034784 | PubTator, text mining | PubMed |
| Overview of Research into mTOR Inhibitors. | Molecules | 2022 | 36014530 | PubTator, text mining | PubMed |
Multiplexed Human Gene Expression Analysis Reveals a Central Role of the TLR/mTOR/PPARγ and NFkB Axes in Burn and Inhalation Injury-Induced Changes in Systemic Immunometabolism and Long-Term Patient Outcomes. | Int J Mol Sci | 2022 | 36012680 | PubTator, text mining | PubMed |
| mTOR: A Potential New Target in Nonalcoholic Fatty Liver Disease. | Int J Mol Sci | 2022 | 36012464 | PubTator, text mining | PubMed |
| Single Cell Analysis of Cultivated Fibroblasts from Chronic Pancreatitis and Pancreatic Cancer Patients. | Cells | 2022 | 36010660 | PubTator, text mining | PubMed |
| Role of microRNAs in B-Cell Compartment: Development, Proliferation and Hematological Diseases. | Biomedicines | 2022 | 36009551 | PubTator, text mining | PubMed |
| The ClinGen Brain Malformation Variant Curation Expert Panel: Rules for somatic variants in AKT3, MTOR, PIK3CA, and PIK3R2. | Genet Med | 2022 | 35997716 | PubTator, text mining | PubMed |
| Genetic impairment of succinate metabolism disrupts bioenergetic sensing in adrenal neuroendocrine cancer. | Cell Rep | 2022 | 35977518 | PubTator, text mining | PubMed |
| MKK6 deficiency promotes cardiac dysfunction through MKK3-p38γ/δ-mTOR hyperactivation. | Elife | 2022 | 35971771 | PubTator, text mining | PubMed |
| Role of PI3K/AKT pathway in squamous cell carcinoma with an especial focus on head and neck cancers. | Cancer Cell Int | 2022 | 35964082 | PubTator, text mining | PubMed |
| mTOR Complex 1 Content and Regulation Is Adapted to Animal Longevity. | Int J Mol Sci | 2022 | 35955882 | PubTator, text mining | PubMed |
| Molecular Mechanisms Underlying Intensive Care Unit-Acquired Weakness and Sarcopenia. | Int J Mol Sci | 2022 | 35955530 | PubTator, text mining | PubMed |
| Expression characteristic, immune signature, and prognosis value of EFNA family identified by multi-omics integrative analysis in pan-cancer. | BMC Cancer | 2022 | 35945523 | PubTator, text mining | PubMed |
| The regulation of skin homeostasis, repair and the pathogenesis of skin diseases by spatiotemporal activation of epidermal mTOR signaling. | Front Cell Dev Biol | 2022 | 35938153 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64798/papers?page=16